JAK1 and Cognitive impairment: Potential drugs include Sunitinib, a tyrosine kinase inhibitor (similar to Donepezil) that remedies cognitive impairments [144], Bosutinib, a dual Abelson/Src inhibitor that promotes autophagy to remove Aβ protein aggregates [145], and Ruxolitinib, a JAK1/2 inhibitor to alleviate neuroinflammation and delay gliogenesis [146, 147] Supplementary Fig. 13B, 13D and 14B, 14D).